MKMiriam Kimel

Miriam Kimel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Miriam Kimel has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Psychometric Validation of the Weight and Emotions Scale (WES) in Adults with Obesity or Overweight

    by Chisom Kanu, Hayley Karn, Claudine Clucas, Iris Goetz, Lisa M. Neff, Kristina S. Boye, Miriam Kimel

    Individuals with obesity or overweight experience a substantial socioemotional burden and lower quality of life. Existing patient-reported outcome (PRO) instruments do not adequately measure emotional functioning concepts important to individuals with obesity/overweight. This study describes the psychometric properties of the Weight and Emotions Scale (WES), a new PRO measure to evaluate emotional functioning in adults with obesity or overweight. 120 adults completed two web-based surveys (baseline, week 2). Survey 1 comprised the 16-item WES, Control of Eating Questionnaire, Impact of Weight on Quality of Life-Lite Clinical Trials Version, Impact of Weight on Self-Perceptions Questionnaire, and Patient Global Impression of Severity (PGIS) 'Overall Emotional Impact of Weight.' Survey 2 included the WES and PGIS 'Overall Emotional Impact of Weight.' Factor structure, reliability, and validity of the WES were assessed. Exploratory factor analysis of the WES supported a two-factor structure as items loaded strongly (≥ 0.59) on factors corresponding to positive and negative feelings. The unidimensional framework was revised to include two WES domains ('Positive Feelings' [8 items] and 'Negative Feelings' [8 items]). The WES domain and total scores demonstrated excellent internal consistency (Cronbach's alpha ≥ 0.90) and good test-retest reliability (intraclass correlation coefficient: 0.87-0.89). Convergent validity of the WES was demonstrated via large correlations with the Impact of Weight on Quality of Life-Lite Clinical Trials Version 'Psychosocial' score and items, Impact of Weight on Self-Perceptions Questionnaire total score, and PGIS 'Overall Emotional Impact of Weight.' Known-groups validity was demonstrated via higher WES domain and total scores in participants who reported feeling good about their weight (PGIS 'Overall Emotional Impact of Weight'). The final version of the WES with 16 items is a reliable and valid PRO measure for assessing emotional functioning in individuals with obesity or overweight, with potential utility in observational studies, clinical trials, and clinical practice.

  • Open Access

    Development of the Weight and Emotions Scale (WES)

    by Chisom Kanu, Miriam Kimel, Iris Goetz, Lisa M. Neff, Kristina S. Boye, Marissa Stefan, Jessica Jordan

    Objective: Obesity and overweight are associated with significant psychosocial burden. Existing patient‐reported outcome (PRO) measures only assess a subset of emotion‐related concepts that are relevant to individuals living with these conditions. The Weight and Emotions Scale (WES) was developed to enable robust evaluation of the impact of obesity or overweight and the benefits of treatment on patients' emotional functioning. Methods: The WES was developed based on findings from interviews with participants ( N = 40) exiting a Phase 2 trial for retatrutide (NCT04881760), a targeted literature review, and interviews with clinicians specialized in obesity medicine ( N = 3). Cognitive interviews were conducted with adults with obesity/overweight and ≥ 1 obesity‐related complication ( N = 20) to evaluate the WES content. Results: All cognitive interview participants expressed a positive overall impression of the WES, reported that they understood the instructions, response options, and recall period, and that the questions were easy to answer. Most items (75%) were understood by all the participants and were rated as “very important” or “moderately important” by ≥ 75% of the participants. The WES is a new 16‐item PRO measure evaluating 13 emotion‐related concepts. Conclusions: The WES may be used in clinical trials, observational research, or clinical practice to robustly assess the impact of obesity or overweight and the benefits of treatment on patients' emotional functioning.


  • Open Access

    Psychometric Validation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity or Overweight

    by Chisom Kanu, Miriam Kimel, Claudine Clucas, Iris Goetz, Lisa M. Neff, Kristina S. Boye, Hayley Karn

    Introduction Obesity management medications influence eating behavior and promote substantial weight reduction in individuals with obesity or overweight. Existing patient-reported outcome measures do not adequately measure appetite and eating behavior concepts relevant to individuals with these conditions. This study presents psychometric properties of the Eating Behavior and Appetite Questionnaire (EBAQ), a new patient-reported outcome measure to assess appetite and eating behaviors in adults with obesity or overweight. Methods Participants (n = 120) completed two web-based surveys (baseline, week 2). Survey 1 included the 21-item EBAQ, Control of Eating Questionnaire, Food Cravings Questionnaire-Trait-reduced, Impact of Weight on Quality of Life-Lite Clinical Trials Version, and Patient Global Impression of Severity (PGIS) items for appetite, eating control, cravings, and overall eating behavior. Survey 2 included the EBAQ and PGIS items. Factor structure, reliability, and validity of the EBAQ were assessed. Results Exploratory factor analysis of the EBAQ supported a 2-factor structure. Items loaded moderately to strongly (≥ 0.48) on factors corresponding to appetite control or eating behavior (inter-factor correlation 0.57). Four items with factor loadings ≤ 0.43 were dropped. Internal consistency for the 17-item EBAQ was good/excellent for the domain scores (0.84–0.91) and excellent for the total score (0.92). Test–retest reliability was good (intraclass correlation coefficients ≥ 0.84). Convergent validity was demonstrated via large correlations with the Control of Eating Questionnaire craving subscales, Food Cravings Questionnaire-Trait-reduced total score, and PGIS items, and smaller correlations with less similar PRO measures. EBAQ domain and total scores demonstrated known-groups validity, with higher EBAQ scores in participants who reported a well-controlled appetite, feeling in control of their eating, fewer food cravings, and better eating habits (i.e., higher PGIS scores). Conclusion Results support the 2-factor structure, reliability, and validity of the final 17-item EBAQ. The EBAQ can be used in observational studies, clinical trials, and clinical practice to comprehensively assess appetite and eating behaviors in individuals with obesity or overweight.


  • Open Access

    Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial

    by Iris A. Goetz, Chisom Kanu, Anastasia Hoover, Cecilia Jimenez-Moreno, Hayley Karn, Miriam Kimel, Lisa M. Neff, Kristina S. Boye